Truist Securities on AdaptHealth (AHCO): 'Remain bullish on AHCO'

Truist Securities analyst David MacDonald reiterated a Buy rating and $13.00 price target on AdaptHealth (NASDAQ: AHCO).

The analyst comments "Remain bullish on AHCO post upbeat management meetings highlighting strong positioning in a fragmented market with attractive overarching tailwinds. Core trends are solid across much of the biz, and while ongoing improvement in Diabetes remains key, we are encouraged by recent progress. The HUM contract is performing well and given AHCO’s scale/breadth of services/ability to drive cost savings/outcomes we expect additional contracts over time, are upbeat on operational rigor/standardization focus and see an attractive AI/automation opportunity. Financial flexibility/FCF remain attractive & we view AHCO as well positioned around potential M&A. Reiterate Buy, $13 PT. "

For an analyst ratings summary and ratings history on AdaptHealth click here. For more ratings news on AdaptHealth click here.

Shares of AdaptHealth closed at $9.01 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
• Aurora Spine settles patent dispute, secures $600K insider loan